Trials / Completed
CompletedNCT05487404
A Clinical Trial to Evaluate the Safety and Efficacy of ADX-629 in in Subjects With Elevated Ethanol Levels
A Double-Blind Clinical Trial to Assess the Interaction Between ADX-629 and Ethanol While Exploring the Safety, Tolerability, and Activity of ADX-629 in Subjects With Elevated Ethanol Levels
- Status
- Completed
- Phase
- Phase 1 / Phase 2
- Study type
- Interventional
- Enrollment
- 26 (actual)
- Sponsor
- Aldeyra Therapeutics, Inc. · Industry
- Sex
- All
- Age
- 21 Years – 65 Years
- Healthy volunteers
- Not accepted
Summary
A Double-Blind Trial to Assess the Interaction Between ADX-629 and Ethanol While Exploring the Safety, Tolerability, and Activity of ADX-629 in Subjects With Elevated Ethanol Levels
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | ADX-629 | 3 oral doses of ADX-629 600 milligrams |
| DRUG | Placebo | 3 oral doses of placebo |
Timeline
- Start date
- 2021-11-15
- Primary completion
- 2022-05-29
- Completion
- 2022-05-29
- First posted
- 2022-08-04
- Last updated
- 2025-02-28
- Results posted
- 2025-02-28
Locations
1 site across 1 country: United States
Regulatory
- FDA-regulated drug study
Source: ClinicalTrials.gov record NCT05487404. Inclusion in this directory is not an endorsement.